CD8A and neoplasm: Adoptive transfer experiments using TIGIT−/− Tregs exhibited tumor inhibition and enhanced pro-inflammatory cytokine production by CD8+ tumor-infiltrating lymphocytes (TILs) (60), which confirmed that TIGIT inhibits anti-tumor immunity predominantly by regulating Treg function.